Docetaxel with prednisone or prednisolone for the treatment of ...

More documents

Recommendations

Info

114 Appendix 2 Study details Reason for exclusion Diaz (2004) 134 Commentary/overview Dogliotti (2003) 135 Commentary/overview Dowling (2000) 136 Background Drummond (1997) 24 Background Efficace (2003) 137 Wrong patient group Eisenberger (1998) 12 Background Esper (1997) 84 Commentary/overview Eymard (2004) 138 Duplicate Fakih (2002) 139 Background Ferrero (2004) 140 Background Ferrero (2003) 141 Not an RCT Fichtner (2000) 142 Commentary/overview Font (2005) 143 Not an RCT Fossa (2001) 144 Background Freeman (2003) 145 Not an RCT Friedland (1999) 146 Not an RCT Gaffar (2003) 147 Not an RCT Garcia-Altes (2001) 148 Background Gilligan (2002) 149 Not an RCT Goodin (2003) 150 Wrong patient group Gravis (2001) 151 Not an RCT Gravis (2003) 152 Background Gravis (2002) 153 Not an RCT Gronberg (2003) 5 Background Guimaraes (2002) 154 Not an RCT Gustafson (2003) 155 Commentary/overview Hainsworth (2004) 156 Background Halabi (2003) 157 Not an RCT Heidenreich (2004) 158 Background Heidenreich (2003) 159 Not an RCT Heidenreich (2003) 160 Not an RCT Heidenreich (2004) 161 Not an RCT Heidenreich (2003) 162 Not an RCT Heidenreich (2003) 163 Not an RCT Hennequin (2004) 164 Commentary/overview Higano (2004) 165 Not an RCT Higano (2004) 166 Not an RCT Hussain (1999) 167 Background Joint Formulary Committee (2005) 18 Background Joly (2004) 168 Background Karavasilis (2003) 169 Not an RCT Kasamon (2004) 170 Commentary/overview Khalaf (2002) 171 Not an RCT Khan (2003) 172 Background Kish (2001) 173 Commentary/overview Knox (2001) 174 Commentary/overview Ko (2001) 175 Wrong intervention drug combination Kolodziej (2002) 176 Not an RCT Kornblith (2001) 177 Not an RCT Kosty (2001) 178 Not an RCT Kozloff (2000) 179 Not an RCT Kozloff (2001) 180 Not an RCT Kuebler (2003) 181 Not an RCT Laber (2002) 182 Not an RCT Laber (2003) 183 Not an RCT Lara (2004) 184 No prednisone/prednisolone (not licensed) Loblaw (2004) 185 Wrong patient group Logothetis (2002) 186 Commentary/overview Lubiniecki (2004) 187 Background Martel (2003) 188 Commentary/overview continued
Study details Reason for exclusion © Queen’s Printer and Controller of HMSO 2007. All rights reserved. Health Technology Assessment 2007; Vol. 11: No. 2 Mattioli (1998) 189 Not an RCT MedlinePlus (2005) 190 Background Miller (2002) 191 Not an RCT Miller (2003) 192 Not an RCT Montero (2005) 193 Background Moore (1994) 194 Not an RCT Muthuramalingam (2004) 9 Background Nabhan (2005) 195 Background National Cancer Institute (1999) 196 Not an RCT National Cancer Institute (2000) 197 No prednisone/prednisolone (not licensed) National Cancer Institute (2002) 198 No prednisone/prednisolone (not licensed) National Cancer Institute (2002) 199 Not an RCT National Cancer Institute (2002) 200 Not an RCT National Cancer Institute (2004) 201 No prednisone/prednisolone (not licensed) National Cancer Institute (2004) 202 No prednisone/prednisolone (not licensed) National Cancer Institute (2004) 203 Not an RCT National Cancer Institute (2004) 204 No prednisone/prednisolone (not licensed) National Cancer Institute (2004) 205 Not an RCT National Cancer Institute (2004) 206 Not an RCT National Cancer Institute (2004) 207 Not an RCT National Cancer Institute (2004) 208 Not an RCT National Cancer Institute (2004) 209 Not an RCT National Cancer Institute (2004) 210 Wrong intervention drug combination National Cancer Institute (2005) 211 Wrong patient group National Cancer Institute (2005) 212 Wrong patient group National Cancer Institute (2005) 213 Wrong patient group National Cancer Institute (2005) 214 Wrong patient group National Cancer Institute (2000) 215 Duplicate report National Cancer Institute (2002) 216 Not an RCT National Cancer Institute (2002) 217 Not an RCT National Cancer Institute (2004) 218 Wrong patient group National Cancer Institute (2005) 219 Not an RCT National Cancer Institute (2005) 220 Wrong intervention drug combination National Cancer Institute 221 Wrong patient group National Cancer Institute 222 Not an RCT National Cancer Institute 223 Not an RCT National Cancer Institute 224 Not an RCT National Horizon Scanning Centre (2003) 19 Background National Institute for Clinical Excellence (2002) 8 Background Newling (1999) 225 Commentary/overview Office for National Statistics (2002) 3 Background Oh (2000) 226 Commentary/overview Oh (1998) 227 Commentary/overview Olson (2000) 228 Commentary/overview Parmar (1998) 25 Background Parvez (2003) 229 Commentary/overview Petrioli (2003) 230 Not an RCT Petrylak (1999) 231 Commentary/overview Petrylak (2000) 232 Commentary/overview Petrylak (2000) 233 Not an RCT Petrylak (2002) 13 Background Petrylak (2002) 234 Commentary/overview Picus (1999) 235 Commentary/overview Picus (1999) 236 Not an RCT Pozzessere (2002) 237 Not an RCT Price (2004) 238 Commentary/overview Raghavan (2002) 239 Not an RCT Rago (2003) 240 Not an RCT Rajasenan (2001) 241 Not an RCT Rexer (2004) 242 Commentary/overview continued 115
Page 1 and 2:
A systematic review and economic mo
Page 3 and 4:
A systematic review and economic mo
Page 5 and 6:
Objectives: A systematic review was
Page 7 and 8:
Glossary and list of abbreviations
Page 9 and 10:
Glossary Absolute risk reduction Th
Page 11 and 12:
Glossary continued Expected value o
Page 13 and 14:
Glossary continued Progression-free
Page 15:
List of abbreviations ASCO American
Page 18 and 19:
xvi Executive summary of study desi
Page 20 and 21:
xviii Executive summary prednisone/
Page 23 and 24:
Description of underlying health pr
Page 25 and 26:
● Patients with severe fluid rete
Page 27 and 28:
Search strategy As stated in Chapte
Page 29 and 30:
consensus and, if necessary, a thir
Page 31 and 32:
Quantity of research available A to
Page 33 and 34:
TABLE 1 Summary of included RCTs St
Page 35 and 36:
TABLE 2 Treatment comparisons relat
Page 37 and 38:
tumour response was reported for on
Page 39 and 40:
TABLE 4 Summary results table for d
Page 41 and 42:
decrease in PSA level (51 and 39% c
Page 43 and 44:
Survival (%) 100 80 60 40 20 0 0 co
Page 45 and 46:
TABLE 8 Summary results table for d
Page 47 and 48:
TABLE 9 Grade 3 or 4 adverse events
Page 49 and 50:
Also used was the core questionnair
Page 51 and 52:
these, 69 patients had measurable t
Page 53 and 54:
Effectiveness of mitoxantrone plus
Page 55 and 56:
over to receive additional mitoxant
Page 57 and 58:
Progression-free survival It is not
Page 59 and 60:
compared with corticosteroids. The
Page 61 and 62:
statistically significant improveme
Page 63 and 64:
Summary of studies included in the
Page 65 and 66:
TABLE 19 Percentage of costs by res
Page 67 and 68:
TABLE 21 Summary of submission by S
Page 69 and 70:
TABLE 24 Other in-trial costs a bod
Page 71 and 72:
TABLE 27 Cost-effectiveness results
Page 73 and 74:
Introduction The review of cost-eff
Page 75 and 76:
TABLE 28 Regression coefficients fr
Page 77 and 78:
cancer QoL estimation. Studies whic
Page 79 and 80:
Localised Metastatic mHRPC Bennet (
Page 81 and 82:
TABLE 34 Unit costs of drugs from t
Page 83 and 84: were assigned to the total follow-u
Page 85 and 86: Probability cost-effective given da
Page 87 and 88: Probability cost-effective given da
Page 89 and 90: TABLE 43 Utility values including/e
Page 91 and 92: was set to be 1.5 years based on th
Page 93: Population value of implementation/
Page 96 and 97: 76 Discussion (CCI-NOV22) and least
Page 98 and 99: 78 Discussion subsequent chemothera
Page 101: Rodolphe Perard received funding fr
Page 104 and 105: 84 References Compendium; 2004. URL
Page 106 and 107: 86 References (D) in patients (pts)
Page 108 and 109: 88 References 100. Aventis Pharma.
Page 110 and 111: 90 References low-dose prednisone i
Page 112 and 113: 92 References 180. Kozloff M, Robin
Page 114 and 115: 94 References locally advanced pros
Page 116 and 117: 96 References 251. Scholz MC, Guess
Page 119 and 120: Clinical effectiveness Searching fo
Page 121 and 122: 1. Prostatic Intraepithelial Neopla
Page 123 and 124: 19. donataxel 20. doxetal 21. doxmi
Page 125 and 126: 6. Mitozantrone.ti,ab. 7. Mitoxantr
Page 127 and 128: Texot or Trazoteva or Trixotene or
Page 129 and 130: 1. (docetaxel OR asodecel OR doxeta
Page 131 and 132: 10. (index of wellbeing or quality
Page 133: Appendix 2 Excluded studies Study d
Page 137 and 138: Meeting: 2004 ASCO Annual Meeting C
Page 139 and 140: Studies of clinical effectiveness w
Page 141 and 142: Using the method outlined by Parmar
Page 143 and 144: Appendix 6 Data extraction tables
Page 145 and 146: Study details and Participant detai
Page 175: Study details and Participant detai
Page 178 and 179: 158 Appendix 7 Ernst et al. 33 Qual
Page 181 and 182: Appendix 9 © Queen’s Printer and
Page 183 and 184: Sanofi-Aventis 61 Bloomfield et al.
Page 185:
Sanofi-Aventis 61 Bloomfield et al.
Page 188 and 189:
168 Appendix 10 TABLE 51 Mean (SD)
Page 190 and 191:
170 Appendix 10 TABLE 54 Distributi
Page 192 and 193:
172 Appendix 10 TABLE 57 Mean stand
Page 194 and 195:
174 Appendix 11 TABLE 63 Drug and a
Page 196 and 197:
176 Appendix 12 Scenario: moderate
Page 198 and 199:
178 Appendix 13 ● You occasionall
Page 202 and 203:
Members Chair, Professor Tom Walley
Page 204 and 205:
Members Chair, Professor Bruce Camp
Page 207:
Feedback The HTA Programme and the
show all

Docetaxel with prednisone or prednisolone for the treatment of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?